Vermillion
(NASDAQ: VRML)
2.77
-0.02
-0.72%
-0.02
-0.72%
MORE ON VRML
COMPANY INFORMATION
| Exchange: | NASDAQ national market |
| Stock: | Vermillion, Inc. |
| Industry: | Diagnostics & Research |
| Employees: | 20 |
DESCRIPTION
| Vermillion, Inc., was originally incorporated in California on December 9, 1993, under the name Abiotic Systems. In March 1995, Abiotic Systems changed its corporate name to Ciphergen Biosystems, Inc. and on June 21, 2000, it reincorporated in Delaware. The Company is engaged in discovery; development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. It uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers for developing a procedure to measure a property or concentration of an analyte, known as an 'assay' and commercializing novel diagnostic tests. The Company’s product, OVA1, was cleared by the United States Food and Drug Administration (FDA) on September 11, 2009. OVA1 addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The Company has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. In the field of peripheral arterial disease, it has identified candidate biomarkers that may help to identify individuals at high risk for a decreased ankle-brachial index score, which is indicative of the likely presence of peripheral arterial disease. It has recently completed an intended-use study to develop and validate a multi-marker algorithm for the assessment of individuals at risk for peripheral arterial disease. This algorithm will be specifically directed at a primary care population in which the peripheral arterial disease blood test (VASCLIR™) is expected to be used. Current and former academic and research institutions that the Company has collaborations with include The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch 'UTMB'; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital; The Ohio State University Research Foundation; and Stanford University. The Company has been subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens and hazardous waste as well as to the safety and health of laboratory employees. |
DATA PROVIDERS
Copyright © 2013 Microsoft. All rights reserved.
Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.
RECENT QUOTES
WATCHLIST
You're not signed in
You’re not signed in to MSN Money, so you’re seeing the Watchlist that is tied to your computer. For a more consistent Watchlist experience, sign in to MSN Money.
Learn more
Sponsored by:
MARKET UPDATE
[BRIEFING.COM] The major averages ended higher across the board as the S&P 500 advanced 0.8%. Equities climbed steadily since the opening bell as investors prepared for tomorrow's policy decision from the Federal Reserve. Although chatter in recent w
...
More
MORE MARKET NEWS
Sponsored by: